Tongling Jieya Biologic Technology Co., Ltd. (SZSE:301108) commences share repurchases on April 10, 2024, under the program mandated by the shareholders in the Extraordinary General Meeting held on March 13, 2024. As per the mandate, the company is authorized to repurchase to repurchase CNY 40 million worth of its common shares. The shares will be repurchased at a price of not more than CNY 40 per share.

The purpose of the program is to effectively safeguard the interests of shareholders, enhance investor confidence, comprehensively consider the business development prospects, and combine the company's actual financial status, operating conditions and other factors. All repurchased shares will be canceled and the registered capital will be reduced accordingly. The program will be funded out of the company's over-raised funds.

The program will be valid till 6 months from the date of approval by shareholders.